SCHEMBL6502655

SCHEMBL6502655

COc1ccccc1C(C=O)c1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
NFE2L2 Q16236 1/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP1B1 Q16678 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
TSHR P16473 1/20 0.38
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3911268 0.86 IDO1 (0.50) CYP19A1IDO1TDO2CA1CA2
SCHEMBL5320250 0.82 GAA (0.32) CYP19A1CYP11B1CYP11B2NFE2L2
SCHEMBL7463502 0.81 MAOB (0.42) IDO1TDO2CA1CA2TSHR
SCHEMBL6501428 0.80 GAA (0.41) CYP1A2CYP2D6TSHRMAPTKDM4E
SCHEMBL5317299 0.77 MAPKAPK2 (0.40) CYP19A1CYP11B1CYP11B2SMN1; SMN2TSHR
SCHEMBL3398965 0.77 CYP19A1 (0.39) CYP19A1NFE2L2IDO1TDO2TSHR
SCHEMBL6508159 0.76 ALDH1A1 (0.47) CYP1A1CYP1A2CYP2D6CYP1B1SMN1; SMN2
SCHEMBL28475047 0.76 IDO1 (0.44) CYP19A1NFE2L2SMN1; SMN2IDO1TDO2
SCHEMBL1515763 0.75 SLC6A3 (0.58) CYP2D6POLBMAPTKDM4EHSD17B10
SCHEMBL23882694 0.75 ACHE (0.49) CYP19A1CYP11B1CYP11B2CYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CYP19A1 2827/4885CYP11B1 2166/4885CYP11B2 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.